Semax and selank on TikTok: what the evidence actually shows

What's this video probably claiming?

Based on the caption and hashtags, this Texas-based telehealth provider is likely walking through the benefits of a compounded peptide blend containing semax and selank, two synthetic peptides with origins in Soviet-era neuropharmacology research. Given the BHRT and HRT hashtags alongside peptide-specific tags, the creator is probably framing this as a cognitive and anxiolytic support protocol, possibly positioned alongside hormone optimization. Clinics promoting these blends typically pitch them as nootropic, stress-reducing, and neuroprotective, drawing on animal data and a handful of small Russian clinical trials. The "most recommended" framing in the caption suggests this is being marketed as a go-to combination with implied broad efficacy, which is exactly where the science gets complicated fast.

What does the science actually show?

Semax is an ACTH(4-7) analogue originally developed in Russia for stroke recovery and cognitive impairment. The most-cited human data comes from Shadrina et al. (2010, Molecular Biology) and Dolotov et al. (2006, Journal of Neurochemistry), both showing BDNF and serotonin pathway modulation in rodent models. Human trials are sparse, small, and mostly unpublished outside Russian-language journals, with sample sizes under 60 patients. Selank is a synthetic analogue of tuftsin, studied primarily for generalized anxiety in Russian clinical trials by Semenova et al. (2010, CNS Drug Reviews), showing modest anxiolytic effects comparable to phenibut in short-duration studies of 7 to 14 days. Neither peptide has completed Phase III trials recognized by the FDA. Both are classified as unapproved drugs in the US, meaning zero regulatory-reviewed efficacy or safety data for American patients exists in any formal review process.

Where does the social media noise diverge from clinical reality?

TikTok peptide content almost universally skips the study limitations that matter most. The semax and selank literature suffers from three consistent problems: nearly all positive human data originates from the same cluster of Russian research institutions, most studies lack proper placebo controls, and follow-up periods rarely exceed 4 weeks. When US-based clinics describe these as "neuroprotective" or "anxiety-relieving," they are extrapolating from that limited dataset to a general healthy population, which the studies never actually tested. The combination of the two as a "blend" adds another layer of unverified territory. There are no published pharmacokinetic interaction studies for a semax-selank combination in humans. Stacking two nootropic peptides and calling it a recommended protocol is not clinical medicine. It is pattern-matching from mechanism theories and anecdote, dressed up in clinical language.

What should you actually know?

If you are considering semax or selank through a telehealth platform, there are several non-negotiable things to understand before proceeding. First, both peptides are compounded, meaning they are not FDA-approved and carry no guaranteed purity or potency standards equivalent to an approved drug. Second, the delivery method matters enormously: intranasal administration, which is common for both, has highly variable bioavailability depending on formulation. Third, the BHRT context layered into this video is a flag worth noting. Adding cognitive peptides to hormone protocols without controlled baselines makes it nearly impossible to attribute outcomes to any single intervention. Akopyan et al. (2017, Human Physiology) noted this confounding in combined neuromodulator studies. The honest summary is that both peptides show enough biological plausibility to justify continued research, but the gap between "plausible" and "proven and safe for you" is where patients consistently get misled by compelling short-form content.